TY - JOUR
T1 - Modeling the cancer patient with genetically engineered mice
T2 - Prediction of toxicity from molecule-targeted therapies
AU - Roberts, Reade B.
AU - Arteaga, Carlos L.
AU - Threadgill, David W.
N1 - Funding Information:
We would like to thank members of our labs for suggestions during the development of this review. We also thank Laura Hansen (Creighton University), Blackwell Publishing, and the American Society of Clinical Oncology for providing images for Figure 1 . This work was supported by NCI grants CA92479 and CA84239 to D.W.T., CA62212 and CA80195 to C.L.A., and Cancer Center Support Grants CA16086 (UNC-Lineberger Cancer Center) and CA68485 (Vanderbilt-Ingram Cancer Center).
PY - 2004/2
Y1 - 2004/2
N2 - Current trends foretell the use of cancer treatments customized to each patient. Genetic and molecular profiling of tumors and an increasing number of molecule-targeted therapies contribute to making this a reality. However, as targets of anticancer therapies become specific proteins or pathways, unanticipated side effects may emerge. In addition, the chronic use of these treatments may contribute to the development of degenerative toxicity not predicted by short-term clinical trials. Here we review and propose how genetically engineered mouse models can serve as valuable tools to predict targeted therapy toxicity, as well as to identify allelic variants that predispose individuals to side effects.
AB - Current trends foretell the use of cancer treatments customized to each patient. Genetic and molecular profiling of tumors and an increasing number of molecule-targeted therapies contribute to making this a reality. However, as targets of anticancer therapies become specific proteins or pathways, unanticipated side effects may emerge. In addition, the chronic use of these treatments may contribute to the development of degenerative toxicity not predicted by short-term clinical trials. Here we review and propose how genetically engineered mouse models can serve as valuable tools to predict targeted therapy toxicity, as well as to identify allelic variants that predispose individuals to side effects.
UR - http://www.scopus.com/inward/record.url?scp=1442285909&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=1442285909&partnerID=8YFLogxK
U2 - 10.1016/S1535-6108(04)00032-7
DO - 10.1016/S1535-6108(04)00032-7
M3 - Review article
C2 - 14998487
AN - SCOPUS:1442285909
SN - 1535-6108
VL - 5
SP - 115
EP - 120
JO - Cancer Cell
JF - Cancer Cell
IS - 2
ER -